^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DM002

    i
    Other names: DM002, DM 002, DM-002, BCG012, BCG 012, BCG-012
    Company:
    Biocytogen, Doma Pharma
    Drug class:
    Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate, MUC1-targeted antibody-drug conjugate
    Related drugs:
    over1year
    A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1 (AACR 2023)
    DM002 candidates showed robust anti-tumor activity in multiple CDX and PDX models of lung, breast, gastric and pancreatic cancer; most notably, DM002 candidates outperformed benchmark ADCs in BP0508 lung PDX models. Together, these data indicate that DM002 will be a promising therapeutic drug for patients with HER3 and MUC1 co-expressing tumors.
    Late-breaking abstract
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • MUC1 (Mucin 1)
    |
    ERBB3 expression • MUC1 expression
    |
    DM002 • R3Mab